1 research outputs found
Clinical features and outcomes of Streptococcus anginosus group infective Endocarditis: a multicenter matched cohort study
[EN] Background. Although Streptococcus anginosus group (SAG) endocarditis is considered a severe disease associated with abscess
formation and embolic events, there is limited evidence to support this assumption.
Methods. We performed a retrospective analysis of prospectively collected data from consecutive patients with definite SAG
endocarditis in 28 centers in Spain and Italy. A comparison between cases due to SAG endocarditis and viridans group streptococci
(VGS) or Streptococcus gallolyticus group (SGG) was performed in a 1:2 matched analysis.
Results. Of 5336 consecutive cases of definite endocarditis, 72 (1.4%) were due to SAG and matched with 144 cases due to VGS/
SGG. SAG endocarditis was community acquired in 64 (88.9%) cases and affected aortic native valve in 29 (40.3%). When comparing
SAG and VGS/SGG endocarditis, no significant differences were found in septic shock (8.3% vs 3.5%, P = .116); valve disorder,
including perforation (22.2% vs 18.1%, P = .584), pseudoaneurysm (16.7% vs 8.3%, P = .108), or prosthesis dehiscence (1.4%
vs 6.3%, P = .170); paravalvular complications, including abscess (25% vs 18.8%, P = .264) and intracardiac fistula (5.6% vs 3.5%,
P = .485); heart failure (34.7% vs 38.9%, P = .655); or embolic events (41.7% vs 32.6%, P = .248). Indications for surgery (70.8% vs
70.8%; P = 1) and mortality (13.9% vs 16.7%; P = .741) were similar between groups.
Conclusions. SAG endocarditis is an infrequent but serious condition that presents a prognosis similar to that of VGS/SGG.This work was supported by Plan Nacional de I+D+i
2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes
y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y
Universidades, Spanish Network for Research in Infectious Diseases (REIPI
RD16/0016/0005), co‐financed by the European Development Regional
Fund “A way to achieve Europe,” Operative Program Intelligent Growth
2014–2020. We thank CERCA Programme/Generalitat de Catalunya for
institutional support. J. M. M. received a personal 80:20 research grant
from Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Barcelona, Spain, during 2017–2021